Title

INSIGHT FLU005: An Anti-Influenza Virus Hyperimmune Intravenous Immunoglobulin Pilot Study.

Document Type

Article

Publication Date

2-15-2016

Publication Title

J Infect Dis

Abstract

UNLABELLED: Hemagglutination inhibition (HAI) antibody responses to anti-influenza virus hyperimmune intravenous immunoglobulin (hIVIG) were characterized. Thirty-one patients with influenza during the 2013-2014 season were randomly assigned to receive 0.25 g/kg of hIVIG (n = 16) or placebo (n = 15). For hIVIG recipients, the ratio of geometric mean titers (1 hour after infusion/before infusion) was 4.00 (95% confidence interval [CI], 2.61-6.13) for 2009 pandemic influenza A(H1N1) and 1.76 (95% CI, 1.33-2.32) for influenza A(H3N2) and influenza B. Among patients with 2009 pandemic influenza A(H1N1), ratios for hIVIG (n = 9) versus placebo (n = 8) were higher 1 hour after infusion (3.9 [95% CI, 2.3-6.7]) and sustained through day 3 (2.0 [95% CI, 1.0-4.0]). hIVIG administration significantly increases HAI titer levels among patients with influenza, supporting the need to perform a clinical outcomes study.

CLINICAL TRIALS REGISTRATION: NCT02008578.

Medical Subject Headings

Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Viral; Double-Blind Method; Female; Hemagglutination Inhibition Tests; Humans; Immunization, Passive; Immunoglobulins, Intravenous; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Male; Middle Aged; Pilot Projects; Placebos; Treatment Outcome; Young Adult

PubMed ID

26374911

Volume

213

Issue

4

First Page

574

Last Page

578

Share

COinS